Eli Lilly and Company (LLY) is a leading drug manufacturers - general business with stocks listed in the US. It opened the day at US$889.54 after a previous close of US$891.07. During the day the price has varied from a low of USD883.01 to a high of USD891.945. The latest price was USD886.16 (25 minute delay). Eli Lilly and Company is listed on the NYSE. All prices are listed in US Dollars.
Our top pick for
US stocks
Our top pick for
Copy trading
Our top pick for
Mobile app
Eli Lilly and Company's shares were split on a 2:1 basis on 15 October 1997. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Eli Lilly and Company shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Eli Lilly and Company shares which in turn could have impacted Eli Lilly and Company's share price.
| Open | US$889.54 |
|---|---|
| High | US$891.945 |
| Low | US$883.01 |
| Close | US$886.16 |
| Previous close | US$891.07 |
| Change | US$-4.91 |
| Change % | -0.551% |
| Volume | 537,306 |
| 52-week range | US$513.1223 - US$972.53 |
|---|---|
| 50-day moving average | US$894.0016 |
| 200-day moving average | US$789.8798 |
| Target price | US$1003.35 |
| PE ratio | 107.5723 |
| Dividend yield | US$4.86 (0.59%) |
| Earnings per share (TTM) | US$8.16 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $886.16
| 1 week (2024-09-26) | -2.55% |
|---|---|
| 1 month (2024-09-03) | -7.36% |
| 3 months (2024-07-03) | -1.33% |
| 6 months (2024-04-03) | 14.20% |
| 1 year (2023-10-03) | 68.73% |
|---|---|
| 2 years (2022-10-03) | 175.59% |
| 3 years (2021-10-01) | 285.97% |
| 5 years (2019-10-03) | 725.95% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Eli Lilly and Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eli Lilly and Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Eli Lilly and Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 108x. In other words, Eli Lilly and Company shares trade at around 108x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Eli Lilly and Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.8527. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Eli Lilly and Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Eli Lilly and Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$15.5 billion (£11.8 billion).
The EBITDA is a measure of a Eli Lilly and Company's overall financial performance and is widely used to measure stock profitability.
Over the last 12 months, Eli Lilly and Company's shares have ranged in value from as little as US$513.1223 up to US$972.53. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Eli Lilly and Company's is 0.422. This would suggest that Eli Lilly and Company's shares are less volatile than average (for this exchange).
N/A| Revenue TTM | US$38.9 billion |
|---|---|
| Operating margin TTM | 39.09% |
| Gross profit TTM | US$21.9 billion |
| Return on assets TTM | 13.7% |
| Return on equity TTM | 59.25% |
| Profit margin | 18.86% |
| Book value | 15.062 |
| Market capitalisation | US$790.4 billion |
| EBITDA | US$15.5 billion |
TTM: trailing 12 months
Dividend payout ratio: 55.34% of net profits
Recently Eli Lilly and Company has paid out, on average, around 55.34% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.59% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Eli Lilly and Company shareholders could enjoy a 0.59% return on their shares, in the form of dividend payments. In Eli Lilly and Company's case, that would currently equate to about $4.86 per share.
Eli Lilly and Company's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Eli Lilly and Company's most recent dividend payout was on 9 September 2024. The latest dividend was paid out to all shareholders who bought their shares by 14 August 2024 (the "ex-dividend date").
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Eli Lilly and Company.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 32.36
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Eli Lilly and Company's overall score of 32.36 (as at 12/31/2018) is pretty weak – landing it in it in the 70th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Eli Lilly and Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 0.63/100
Eli Lilly and Company's environmental score of 0.63 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 16.68/100
Eli Lilly and Company's social score of 16.68 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 13.31/100
Eli Lilly and Company's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Eli Lilly and Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Eli Lilly and Company scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Eli Lilly and Company hasn't always managed to keep its nose clean.
Eli Lilly and Company was last rated for ESG on: 2019-01-01.
| Total ESG score | 32.36 |
|---|---|
| Total ESG percentile | 70.22 |
| Environmental score | 0.63 |
| Environmental score percentile | 1 |
| Social score | 16.68 |
| Social score percentile | 1 |
| Governance score | 13.31 |
| Governance score percentile | 1 |
| Level of controversy | 3 |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Looking for the best performing stocks in Australia? We update this list weekly.
Ethical investing is predicted to surge in 2024. Here is what you need to know to be part of this growing trend.
There are 3 main options available to you in Australia if you want to build a portfolio of company stocks
Is online broker Pearler the right choice for you? Find out in this guide to Pearler’s fees and features.
We rate the fees and features of both online brokers.
Here is the essential information you need to know about buying shares for children.
Gain access to the US and Australian markets for less through moomoo share trading accounts.
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
Westpac Share Trading allows you to take control of your investments. Find out if its right for you.
What are managed funds? Read our guide and learn the different types of managed funds available.